No smooth sailing for FDA nominee  © Associated Press/Manuel Balce Ceneta President Biden’s pick to lead the Food and Drug Administration (FDA) is facing surprising headwinds, as Senate Democrats work to build up enough bipartisan support for confirmation. More than two months after being nominated, it’s unclear if Robert Califf has enough votes to be confirmed. At least five Democrats have already spoken out against him, and others remain undecided. At the same time, Republicans are facing pressure from anti-abortion groups, which have mobilized against Califf. He gained just four GOP votes in a committee vote last month. Califf, a cardiologist and Duke University researcher, was confirmed to the same post by a vote of 89-4 in 2016 when he was nominated by former President Obama. Some Democrats said they are still confident Califf will get 50 votes, but there are concerns about extra drama during a process that was supposed to be fairly smooth. “I think he’ll have the votes. But it’s going to be an interesting mix of Republicans and Democrats,” said Sen. Chris Murphy (D-Conn.). Sen. Dick Durbin (Ill.), the No. 2 Senate Democrat, said the votes were “very close.” Dem opposition: Four Democrats — Sens. Joe Manchin (W.Va.), Ed Markey (Mass.), Maggie Hassan (N.H.) and Richard Blumenthal (Conn.) — as well as Sen. Bernie Sanders (I-Vt.), who caucuses with the Democrats, have signaled opposition to Califf’s nomination over his ties to industry and the FDA’s role in the opioid crisis. Since he left government, Califf has advised Google Health and its spinoff, Verily Life Sciences, where he was paid millions in stock and more than $2.7 million in salary and bonuses. Read more here. |
No comments:
Post a Comment